Small gain in ocular melanoma equals big news

Elizabeth whittington blog image

In a cancer that doesn't have many treatment options, any gains are considered a success.

Uveal melanoma, although rare, is the most common eye cancer in adults, affecting nearly 2500 individuals a year. While surgery and radiation are standard treatments, once the disease becomes metastatic it is almost impossible to treat successfully.

Researchers decided to test a MEK inhibitor, selumitinib, in this patient population. The thought was that because most of these tumors express a certain gene mutation it would respond to this particular targeted drug.

No standard treatments exist, which made a control group hard to create, says lead author. Instead of making it a placebo-based trial, researchers compared the MEK inhibitor with a temzolomide, a brain cancer drug that has been used to treat skin cancers.

Details of the clinical trial can be found at

You can find out more about ocular melanoma at the Ocular Melanoma Foundation You can read more about the study at ASCO.

Richard Carvajal

Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center describes the results of the selumetinib study. Photo by ©ASCO/Scott Morgan 2013

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Special Feature
Share Your Art
Related Articles
BRCA Mutations May Cause Drug Resistance in Breast and Ovarian Cancer
There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.
Sarah Sciortino on Fertility and Sexuality in Younger Patients with Ovarian Cancer
Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.
Caring With Confidence: Study Examines Caregiver Mastery and Patient Survival in GBM
A recent study found that the level of family caregiver mastery may have an effect on the survival of patients with glioblastoma.
Related Videos
Examining Quality of Life Issues for Patients With MPNs
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
Elliott Winton on the Changing Landscape of MPN Treatment
Elliott Winton, M.D., researcher, physician and 2016 MPN Hero, discusses some of the drastic changes that happened over the past decade or so in the world of MPNs. 
Siddhartha Mukherjee on Increasing MPN Awareness
Siddhartha Mukherjee, M.D., Ph.D, an oncologist, researcher and Pulitzer Prize-winning science writer, discusses the increasing awareness about myeloproliferative neoplasms (MPNs).
//For side ad protocol